summa up tirzepatide Compound FDA approves tirzepatide to treat

The weight loss effects of semaglutide are primarily due to its action on the GLP-1 receptors, which play a role in appetite regulation and calorie intake

The definition of IC has been defined by the American Urology Association (AUA) as: "An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptom(s) of more than six weeks duration, in the absence of infection or other identifiable causes." AUA 2022

Concomitant use with other GLP-1 receptor agonists or weight-loss medications is not recommended unless specifically directed by a healthcare provider

Xiaobei Ma, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

[PMC free article: PMC4392802] [PubMed: 24092834] 221

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage